Loading...
XJPX4594
Market cap24mUSD
Jan 08, Last price  
45.00JPY
1D
2.27%
1Q
-8.16%
Jan 2017
-93.52%
IPO
-88.64%
Name

BrightPath Biotherapeutics Co Ltd

Chart & Performance

D1W1MN
XJPX:4594 chart
P/E
—
P/S
54,685.19
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.89%
Rev. gr., 5y
-78.47%
Revenues
72k
-98.64%
821,625,000822,556,000529,612,000354,410,000155,808,00011,300,0002,504,00015,408,0005,280,00072,000
Net income
-1.17b
L-21.37%
-412,435,000-994,464,000-1,113,661,000-1,577,142,000-1,884,318,000-1,857,774,000-1,719,634,000-1,484,192,000-1,485,633,000-1,168,082,000
CFO
-1.16b
L-3.94%
-447,197,000-908,711,000-1,067,512,000-1,591,336,000-1,457,571,000-1,784,461,000-1,769,848,000-1,512,022,000-1,204,401,000-1,156,920,000

Profile

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.
URL
https://www.brightpathbio.com/
IPO date
Oct 22, 2015
Employees
42
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
72
-98.64%
5,280
-65.73%
15,408
515.34%
Cost of revenue
775,969
1,170,368
1,139,164
Unusual Expense (Income)
NOPBT
(775,897)
(1,165,088)
(1,123,756)
NOPBT Margin
Operating Taxes
1,900
1,900
2,420
Tax Rate
NOPAT
(777,797)
(1,166,988)
(1,126,176)
Net income
(1,168,082)
-21.37%
(1,485,633)
0.10%
(1,484,192)
-13.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
573,382
519,604
478,051
BB yield
-13.34%
-5.06%
-8.93%
Debt
Debt current
112,500
87,500
Long-term debt
Deferred revenue
Other long-term liabilities
60,258
57,347
55,073
Net debt
(944,860)
(1,530,969)
(2,217,526)
Cash flow
Cash from operating activities
(1,156,920)
(1,204,401)
(1,512,022)
CAPEX
(6,194)
(1,760)
(17,646)
Cash from investing activities
(7,648)
(1,760)
(17,566)
Cash from financing activities
690,959
432,104
569,226
FCF
(792,018)
(891,884)
(1,167,563)
Balance
Cash
1,057,360
1,530,969
2,305,026
Long term investments
Excess cash
1,057,356
1,530,705
2,304,256
Stockholders' equity
(2,003,054)
(1,103,180)
(4,152,493)
Invested Capital
3,154,800
2,717,657
6,787,723
ROIC
ROCE
EV
Common stock shares outstanding
64,162
59,660
51,993
Price
67.00
-61.05%
172.00
66.99%
103.00
-47.18%
Market cap
4,298,872
-58.11%
10,261,567
91.62%
5,355,292
-42.28%
EV
3,354,012
8,730,598
3,137,766
EBITDA
(775,502)
(1,148,369)
(1,088,633)
EV/EBITDA
Interest
1,399
61
362
Interest/NOPBT